Sign up
Pharma Capital

Market is undervaluing Just Eat’s overseas businesses, argues UBS

The Swiss investment bank thinks the market is attributing just £700mln to Just Eat’s assets outside of the UK and Canada, but it argues that the Brazilian joint venture alone is worth more than that
just eat
Just Eat shares have fallen in recent months on fears over Deliveroo and Uber Eats competition

UBS reckons the market is drastically underestimating the value of Just Eat PLC’s (LON:JE.) overseas businesses.

According to the Swiss investment bank, based on the current Just Eat share price, the FTSE 250 group’s Latin American, Brazilian and Australian assets are worth £700mln.

This is “too pessimistic”, UBS argues, especially given that the iFood joint venture in Brazil could easily be valued at upwards of £750mln on its own.

READ: Major Just Eat shareholder calls for merger talks

“iFood has been seen as one of JE's best assets, with triple digit order growth and over 80% market share, particularly after it turned profitable in 1H18,” read a note to clients.

“We think JE share of this asset could be worth £760mln, using precedent transactions multiples, i.e. potentially 15% of the JE share price.”

Just Eat shares have taken a hit in recent months as fears grow over the impact of competition from well-funded upstarts Deliveroo and Uber Eats, while investment in logistics has dented profits.

'Trough in sight'

But after years of negative earnings per share momentum, the analysts believe “the trough is likely in sight”.

“We see multiple positive catalysts in 2019: double-digit year-on-year UK order growth, SkipTheDishes (Canada) turning profitable, and optionality from the sale of Latam assets.”

UBS trimmed its price target to 870p (from 930p) to reflect a “costlier delivery roll-out”, but it kept in place its bullish ‘buy’ recommendation.

Just Eat shares edged 0.7% higher to 735.8p in mid-morning trading on Tuesday.

Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.